[{"id":"f99e9a96-78aa-4611-a09e-0bb82a397f5e","acronym":"","url":"https://clinicaltrials.gov/study/NCT06967103","created_at":"2025-06-07T15:00:18.246Z","updated_at":"2025-06-07T15:00:18.246Z","phase":"Phase 2","brief_title":"QL1706 for the Neoadjuvant Treatment of HR+/HER2- Breast Cancer","source_id_and_acronym":"NCT06967103","lead_sponsor":"Henan Cancer Hospital","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • epirubicin • Qibeian (iparomlimab/tuvonralimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 238","initiation":"Initiation: 05/20/2025","start_date":" 05/20/2025","primary_txt":" Primary completion: 05/31/2027","primary_completion_date":" 05/31/2027","study_txt":" Completion: 05/30/2029","study_completion_date":" 05/30/2029","last_update_posted":"2025-05-13"},{"id":"bf338af6-7bdc-4263-a249-2470acc07fb1","acronym":"","url":"https://clinicaltrials.gov/study/NCT06860529","created_at":"2025-06-07T14:59:59.699Z","updated_at":"2025-06-07T14:59:59.699Z","phase":"Phase 2","brief_title":"Serplulimab Combined with Chemotherapy for Early-stage HR+/HER2- Breast Cancer","source_id_and_acronym":"NCT06860529","lead_sponsor":"Henan Cancer Hospital","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • epirubicin • Hetronifly (serplulimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 357","initiation":"Initiation: 03/01/2025","start_date":" 03/01/2025","primary_txt":" Primary completion: 03/31/2028","primary_completion_date":" 03/31/2028","study_txt":" Completion: 03/31/2030","study_completion_date":" 03/31/2030","last_update_posted":"2025-03-06"},{"id":"2aac339a-fbd4-48aa-9c04-5e7a6adc7234","acronym":"NCI-MATCH","url":"https://clinicaltrials.gov/study/NCT02465060","created_at":"2021-01-17T17:15:30.769Z","updated_at":"2025-02-25T16:36:36.993Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","source_id_and_acronym":"NCT02465060 - NCI-MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["MSI • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Pertuvia (pertuzumab biosimilar) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6452","initiation":"Initiation: 08/17/2015","start_date":" 08/17/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"6d363f74-eebb-42b8-8282-8889b9922b4e","acronym":"TROPION-Breast04","url":"https://clinicaltrials.gov/study/NCT06112379","created_at":"2023-11-01T15:12:45.942Z","updated_at":"2025-02-25T16:40:21.913Z","phase":"Phase 3","brief_title":"A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer","source_id_and_acronym":"NCT06112379 - TROPION-Breast04","lead_sponsor":"AstraZeneca","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lynparza (olaparib) • carboplatin • Imfinzi (durvalumab) • paclitaxel • doxorubicin hydrochloride • capecitabine • cyclophosphamide • epirubicin • Datroway (datopotamab deruxtecan-dlnk)"],"overall_status":"Recruiting","enrollment":" Enrollment 1728","initiation":"Initiation: 11/14/2023","start_date":" 11/14/2023","primary_txt":" Primary completion: 03/29/2028","primary_completion_date":" 03/29/2028","study_txt":" Completion: 08/28/2030","study_completion_date":" 08/28/2030","last_update_posted":"2025-02-06"},{"id":"ed857d81-c1db-430d-8754-fe70af84d781","acronym":"STRASS 2","url":"https://clinicaltrials.gov/study/NCT04031677","created_at":"2021-01-18T19:47:11.156Z","updated_at":"2025-02-25T17:24:14.778Z","phase":"Phase 3","brief_title":"Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma","source_id_and_acronym":"NCT04031677 - STRASS 2","lead_sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","biomarkers":" MDM2 • CDK4","pipe":" | ","alterations":" MDM2 amplification","tags":["MDM2 • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MDM2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • epirubicin"],"overall_status":"Recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 01/20/2021","start_date":" 01/20/2021","primary_txt":" Primary completion: 04/21/2027","primary_completion_date":" 04/21/2027","study_txt":" Completion: 04/21/2028","study_completion_date":" 04/21/2028","last_update_posted":"2025-01-31"},{"id":"d8a6d977-6f13-416a-b8b4-9b7236d1ef6b","acronym":"TAPUR","url":"https://clinicaltrials.gov/study/NCT02693535","created_at":"2021-01-17T17:24:20.327Z","updated_at":"2025-02-25T14:00:57.498Z","phase":"Phase 2","brief_title":"TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer","source_id_and_acronym":"NCT02693535 - TAPUR","lead_sponsor":"American Society of Clinical Oncology","biomarkers":" BRAF","pipe":" | ","alterations":" ER positive • HER-2 negative • PGR positive","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Xalkori (crizotinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Rozlytrek (entrectinib) • sunitinib • tamoxifen • Perjeta (pertuzumab) • Cotellic (cobimetinib) • Bavencio (avelumab) • Talzenna (talazoparib) • Verzenio (abemaciclib) • albumin-bound paclitaxel • cyclophosphamide • Stivarga (regorafenib) • fulvestrant • Lytgobi (futibatinib) • Tukysa (tucatinib) • temsirolimus • letrozole • axitinib • epirubicin • anastrozole • exemestane • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • leuprolide acetate for depot suspension"],"overall_status":"Recruiting","enrollment":" Enrollment 3791","initiation":"Initiation: 03/14/2016","start_date":" 03/14/2016","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2025-01-29"},{"id":"6870ca3c-02f9-433a-a563-a632024b03f4","acronym":"APHINITY","url":"https://clinicaltrials.gov/study/NCT01358877","created_at":"2021-01-17T17:16:38.909Z","updated_at":"2025-02-25T13:59:55.104Z","phase":"Phase 3","brief_title":"A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer","source_id_and_acronym":"NCT01358877 - APHINITY","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • carboplatin • paclitaxel • docetaxel • 5-fluorouracil • Perjeta (pertuzumab) • doxorubicin hydrochloride • cyclophosphamide • epirubicin • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 4804","initiation":"Initiation: 11/08/2011","start_date":" 11/08/2011","primary_txt":" Primary completion: 12/19/2016","primary_completion_date":" 12/19/2016","study_txt":" Completion: 11/28/2024","study_completion_date":" 11/28/2024","last_update_posted":"2025-01-13"},{"id":"5ab5758f-ded0-479b-83dd-b16b495d0f1a","acronym":"FASCINATE-N","url":"https://clinicaltrials.gov/study/NCT05582499","created_at":"2022-10-17T13:56:00.115Z","updated_at":"2025-02-25T12:29:07.250Z","phase":"Phase 2","brief_title":"Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy","source_id_and_acronym":"NCT05582499 - FASCINATE-N","lead_sponsor":"Fudan University","biomarkers":" HER-2 • PGR • CD8 • FOXC1","pipe":"","alterations":" ","tags":["HER-2 • PGR • CD8 • FOXC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • carboplatin • Perjeta (pertuzumab) • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • Irene (pyrotinib) • albumin-bound paclitaxel • cyclophosphamide • letrozole • epirubicin • trastuzumab rezetecan (SHR-A1811) • AiRuiYi (fluzoparib) • AiRuiKang (dalpiciclib) • goserelin acetate • famitinib (SHR 1020) • AiRuiLi (adebrelimab) • tizetatug rezetecan (SHR-A1921)"],"overall_status":"Recruiting","enrollment":" Enrollment 716","initiation":"Initiation: 11/01/2022","start_date":" 11/01/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-12-27"},{"id":"9d739726-be1b-490e-bc9a-406b8d4333a4","acronym":"NEOTORCH-BREAST01","url":"https://clinicaltrials.gov/study/NCT06611813","created_at":"2025-02-26T14:56:34.715Z","updated_at":"2025-02-26T14:56:34.715Z","phase":"Phase 2","brief_title":"Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer (NEOTORCH-BREAST01)","source_id_and_acronym":"NCT06611813 - NEOTORCH-BREAST01","lead_sponsor":"First Affiliated Hospital of Zhejiang University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • Loqtorzi (toripalimab-tpzi) • cyclophosphamide • epirubicin"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 06/11/2024","start_date":" 06/11/2024","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2029","study_completion_date":" 06/01/2029","last_update_posted":"2024-11-15"},{"id":"2c66d4b7-1c2e-4cd1-a61a-2f452cfb4042","acronym":"","url":"https://clinicaltrials.gov/study/NCT06470464","created_at":"2025-02-26T14:17:59.459Z","updated_at":"2025-02-26T14:17:59.459Z","phase":"Phase 2","brief_title":"Thalidomide Combined With Chemotherapy in the Treatment of Relapsed or Refractory Yolk Sac Tumor","source_id_and_acronym":"NCT06470464","lead_sponsor":"Shandong First Medical University","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • albumin-bound paclitaxel • epirubicin • thalidomide"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 11/11/2021","start_date":" 11/11/2021","primary_txt":" Primary completion: 06/16/2024","primary_completion_date":" 06/16/2024","study_txt":" Completion: 06/16/2024","study_completion_date":" 06/16/2024","last_update_posted":"2024-06-24"},{"id":"641e1e85-802d-456b-8ede-12ae69c97226","acronym":"NeoTENNIS","url":"https://clinicaltrials.gov/study/NCT04418154","created_at":"2021-01-18T21:17:40.275Z","updated_at":"2024-07-02T16:35:02.194Z","phase":"Phase 2","brief_title":"Neoadjuvant Dose-dense EC Followed by ABX With PD-1 for Triple Negative Breast Cancer Patients","source_id_and_acronym":"NCT04418154 - NeoTENNIS","lead_sponsor":"Fudan University","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • ER negative • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • albumin-bound paclitaxel • cyclophosphamide • epirubicin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 06/09/2020","start_date":" 06/09/2020","primary_txt":" Primary completion: 09/28/2022","primary_completion_date":" 09/28/2022","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-05-21"},{"id":"78693f94-a4f3-4062-ad70-9abc1451654d","acronym":"","url":"https://clinicaltrials.gov/study/NCT01340430","created_at":"2021-01-18T05:28:15.447Z","updated_at":"2024-07-02T16:35:04.679Z","phase":"Phase 2","brief_title":"Neoadjuvant 5-fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Weekly Paclitaxel and Trastuzumab in Her2 Positive Breast Cancer","source_id_and_acronym":"NCT01340430","lead_sponsor":"Lucia Del Mastro,MD","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • paclitaxel • 5-fluorouracil • cyclophosphamide • epirubicin"],"overall_status":"Completed","enrollment":" Enrollment 43","initiation":"Initiation: 03/01/2011","start_date":" 03/01/2011","primary_txt":" Primary completion: 12/01/2015","primary_completion_date":" 12/01/2015","study_txt":" Completion: 01/01/2022","study_completion_date":" 01/01/2022","last_update_posted":"2024-05-09"},{"id":"013722f8-7414-4a7a-aae8-d8848e4bfda1","acronym":"KEYPARTNER","url":"https://clinicaltrials.gov/study/NCT06371807","created_at":"2024-04-17T20:53:45.791Z","updated_at":"2024-07-02T16:35:09.166Z","phase":"Phase 2","brief_title":"Trial for Treatment of High Risk BC With Two Sequences of Neoadjuvant Chemotherapy With Pembrolizumab","source_id_and_acronym":"NCT06371807 - KEYPARTNER","lead_sponsor":"Fundacao Champalimaud","biomarkers":" CD8 • PD-1","pipe":"","alterations":" ","tags":["CD8 • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • paclitaxel • doxorubicin hydrochloride • cyclophosphamide • epirubicin"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 07/01/2024","start_date":" 07/01/2024","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-04-17"},{"id":"8a57e1c2-20d0-4918-808a-15843ae73aab","acronym":"COC-IDCB","url":"https://clinicaltrials.gov/study/NCT02897700","created_at":"2021-01-18T14:13:12.285Z","updated_at":"2024-07-02T16:35:09.134Z","phase":"Phase 1","brief_title":"A Randomized Trial of Chemotherapy in Surgical Patients With Infiltrating Ductal Carcinoma of Breast","source_id_and_acronym":"NCT02897700 - COC-IDCB","lead_sponsor":"Shanghai Jiao Tong University School of Medicine","biomarkers":" HER-2 • ER • PGR","pipe":"","alterations":" ","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • doxorubicin hydrochloride • cyclophosphamide • epirubicin • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 01/01/2013","start_date":" 01/01/2013","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2024-04-17"},{"id":"953f54f6-a015-4470-87c6-8327cbe57fac","acronym":"PH002-TP-II","url":"https://clinicaltrials.gov/study/NCT03272477","created_at":"2021-01-17T17:20:14.947Z","updated_at":"2025-02-25T13:52:22.823Z","phase":"Phase 2","brief_title":"Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients","source_id_and_acronym":"NCT03272477 - PH002-TP-II","lead_sponsor":"Palleos Healthcare GmbH","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • paclitaxel • tamoxifen • Perjeta (pertuzumab) • cyclophosphamide • letrozole • epirubicin • anastrozole • exemestane • goserelin acetate • leuprolide acetate for depot suspension • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 257","initiation":"Initiation: 10/05/2017","start_date":" 10/05/2017","primary_txt":" Primary completion: 07/14/2020","primary_completion_date":" 07/14/2020","study_txt":" Completion: 03/04/2024","study_completion_date":" 03/04/2024","last_update_posted":"2024-04-17"},{"id":"2eca1275-9ca8-4c95-8c41-ae4a45c7bd91","acronym":"GeparDouze","url":"https://clinicaltrials.gov/study/NCT03281954","created_at":"2021-01-18T16:12:20.934Z","updated_at":"2024-07-02T16:35:11.046Z","phase":"Phase 3","brief_title":"Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo","source_id_and_acronym":"NCT03281954 - GeparDouze","lead_sponsor":"NSABP Foundation Inc","biomarkers":" HER-2 • PD-L1 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • ER negative • PGR negative","tags":["HER-2 • PD-L1 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • carboplatin • paclitaxel • doxorubicin hydrochloride • cyclophosphamide • epirubicin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1550","initiation":"Initiation: 12/19/2017","start_date":" 12/19/2017","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 11/30/2027","study_completion_date":" 11/30/2027","last_update_posted":"2024-04-08"},{"id":"36532377-27fe-4bf6-9ea2-32c3eb2cbc4e","acronym":"TRAIN-2","url":"https://clinicaltrials.gov/study/NCT01996267","created_at":"2021-01-17T17:16:40.952Z","updated_at":"2025-02-25T14:00:18.491Z","phase":"Phase 3","brief_title":"Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2","source_id_and_acronym":"NCT01996267 - TRAIN-2","lead_sponsor":"The Netherlands Cancer Institute","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 overexpression • HER-2 amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 overexpression • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • carboplatin • paclitaxel • 5-fluorouracil • Perjeta (pertuzumab) • cyclophosphamide • epirubicin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 437","initiation":"Initiation: 12/01/2013","start_date":" 12/01/2013","primary_txt":" Primary completion: 12/01/2018","primary_completion_date":" 12/01/2018","study_txt":" Completion: 12/01/2030","study_completion_date":" 12/01/2030","last_update_posted":"2024-03-29"},{"id":"a548212c-cd9c-41ca-9547-6e16050ba508","acronym":"","url":"https://clinicaltrials.gov/study/NCT05862064","created_at":"2023-05-17T14:05:17.924Z","updated_at":"2024-07-02T16:35:13.220Z","phase":"Phase 3","brief_title":"PD-1 Combined With Adjuvant Chemotherapy and Antivascular Therapy Versus Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer","source_id_and_acronym":"NCT05862064","lead_sponsor":"Fudan University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • AiRuiKa (camrelizumab) • cyclophosphamide • epirubicin"],"overall_status":"Recruiting","enrollment":" Enrollment 606","initiation":"Initiation: 06/01/2023","start_date":" 06/01/2023","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2024-03-22"},{"id":"b182b0af-c64f-4e09-899b-fb596cb0fc9d","acronym":"ARIADNE","url":"https://clinicaltrials.gov/study/NCT05900206","created_at":"2023-06-12T15:09:02.469Z","updated_at":"2025-02-25T13:55:17.377Z","phase":"Phase 2","brief_title":"Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer","source_id_and_acronym":"NCT05900206 - ARIADNE","lead_sponsor":"Karolinska University Hospital","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • carboplatin • paclitaxel • docetaxel • Perjeta (pertuzumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • cyclophosphamide • Kisqali (ribociclib) • letrozole • epirubicin"],"overall_status":"Recruiting","enrollment":" Enrollment 370","initiation":"Initiation: 10/26/2023","start_date":" 10/26/2023","primary_txt":" Primary completion: 04/30/2027","primary_completion_date":" 04/30/2027","study_txt":" Completion: 04/30/2032","study_completion_date":" 04/30/2032","last_update_posted":"2024-03-08"},{"id":"92d049be-73d0-4ea0-8eaf-f039e76f1242","acronym":"ETNA","url":"https://clinicaltrials.gov/study/NCT01822314","created_at":"2021-01-18T08:04:39.209Z","updated_at":"2024-07-02T16:35:15.989Z","phase":"Phase 3","brief_title":"Neoadjuvant Chemotherapy With Nab-paclitaxel in Women With HER2-negative High-risk Breast Cancer","source_id_and_acronym":"NCT01822314 - ETNA","lead_sponsor":"Fondazione Michelangelo","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • PGR positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • albumin-bound paclitaxel • cyclophosphamide • epirubicin"],"overall_status":"Completed","enrollment":" Enrollment 632","initiation":"Initiation: 04/01/2013","start_date":" 04/01/2013","primary_txt":" Primary completion: 09/01/2016","primary_completion_date":" 09/01/2016","study_txt":" Completion: 03/01/2023","study_completion_date":" 03/01/2023","last_update_posted":"2024-03-07"},{"id":"0ac61cbf-3e9f-4af1-95a4-5ca408d4fa59","acronym":"NeoTRIPaPDL1","url":"https://clinicaltrials.gov/study/NCT02620280","created_at":"2021-01-18T12:43:52.463Z","updated_at":"2024-07-02T16:35:16.015Z","phase":"Phase 3","brief_title":"Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1","source_id_and_acronym":"NCT02620280 - NeoTRIPaPDL1","lead_sponsor":"Fondazione Michelangelo","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" PD-L1 expression • HER-2 negative • ER negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 negative • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • carboplatin • doxorubicin hydrochloride • albumin-bound paclitaxel • cyclophosphamide • epirubicin"],"overall_status":"Completed","enrollment":" Enrollment 278","initiation":"Initiation: 04/01/2016","start_date":" 04/01/2016","primary_txt":" Primary completion: 01/01/2024","primary_completion_date":" 01/01/2024","study_txt":" Completion: 01/07/2024","study_completion_date":" 01/07/2024","last_update_posted":"2024-03-06"},{"id":"70a796c5-0ee4-4969-94a9-6b00497819a1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05474690","created_at":"2022-07-26T17:10:08.780Z","updated_at":"2025-02-25T13:54:35.379Z","phase":"Phase 3","brief_title":"A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer","source_id_and_acronym":"NCT05474690","lead_sponsor":"Henan Cancer Hospital","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • carboplatin • docetaxel • Perjeta (pertuzumab) • cyclophosphamide • epirubicin"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 05/11/2022","start_date":" 05/11/2022","primary_txt":" Primary completion: 03/28/2023","primary_completion_date":" 03/28/2023","study_txt":" Completion: 08/30/2024","study_completion_date":" 08/30/2024","last_update_posted":"2024-02-26"},{"id":"3e2d3adf-cbbc-4fde-a2d7-6ee040049224","acronym":"B-IMMUNE","url":"https://clinicaltrials.gov/study/NCT03356860","created_at":"2021-01-18T16:34:14.836Z","updated_at":"2024-07-02T16:35:17.991Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer.","source_id_and_acronym":"NCT03356860 - B-IMMUNE","lead_sponsor":"Grand Hôpital de Charleroi","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • paclitaxel • cyclophosphamide • epirubicin • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 57","initiation":"Initiation: 04/13/2017","start_date":" 04/13/2017","primary_txt":" Primary completion: 11/21/2022","primary_completion_date":" 11/21/2022","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2024-02-23"},{"id":"fa0a16d9-bc9f-4cf1-a454-6909e3b1d1b2","acronym":"TavIx","url":"https://clinicaltrials.gov/study/NCT00630032","created_at":"2021-01-18T02:20:34.220Z","updated_at":"2024-07-02T16:35:18.454Z","phase":"Phase 3","brief_title":"Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer","source_id_and_acronym":"NCT00630032 - TavIx","lead_sponsor":"UNICANCER","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • HR negative • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • HR negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • 5-fluorouracil • cyclophosphamide • epirubicin • Ixempra (ixabepilone)"],"overall_status":"Completed","enrollment":" Enrollment 762","initiation":"Initiation: 09/01/2007","start_date":" 09/01/2007","primary_txt":" Primary completion: 06/01/2017","primary_completion_date":" 06/01/2017","study_txt":" Completion: 09/03/2020","study_completion_date":" 09/03/2020","last_update_posted":"2024-02-21"}]